ESMO: Sanofi/Regeneron’s Latecomer Anti-PD-1 Libtayo Looking Likely In NSCLC

Libtayo Shows 32% OS Benefit In EMPOWER-Lung 1

 
• By Alexandra Shimmings
  
lung illustration
• Source: Shutterstock

More from Clinical Trials

More from R&D